Role of naofen, a novel wd repeat-containing protein, in reducing nitric oxide-induced relaxation

Clinical and Experimental Pharmacology and Physiology

Volumn 35, Issue 12, 2008, Pages 1447-1453

  Feng, Guo Gang ^a   Yamada, Mitsuru ^a   Wongsawatkul, Orapin ^b   Li, Chang ^a   Huang, Lei ^a   An, Jun ^a   Komatsu, Toru ^a   Fujiwara, Yoshihiro ^a   Naohisa, Ishikawa ^a  

^a AICHI MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b SRINAKHARINWIROT UNIVERSITY   (Thailand)

Author keywords

Aorta; Deoxycorticosterone acetate; GTP cyclohydrolase I; Hypertension; Naofen; Nitric oxide

Indexed keywords

ACETYLCHOLINE; CELL PROTEIN; CYCLOHYDROLASE I; DEOXYCORTICOSTERONE ACETATE; HYDROLASE; NAOFEN; NITRIC OXIDE; POTASSIUM; RENIN; SODIUM; UNCLASSIFIED DRUG; VEROTOXIN 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; BLOOD VESSEL REACTIVITY; CONTROLLED STUDY; ELECTROLYTE BLOOD LEVEL; ENDOTHELIUM CELL; GENE EXPRESSION; HEART RATE; HYPERTENSION; IMMUNOHISTOCHEMISTRY; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PLASMA RENIN ACTIVITY; RAT; THORACIC AORTA; WISTAR KYOTO RAT;

ACETYLCHOLINE; ANIMALS; AORTA, THORACIC; CELL LINE; MALE; MICE; NITRIC OXIDE; PROTEINS; RATS; RATS, INBRED WKY; VASODILATION;

EID: 55349108566     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2008.05008.x     Document Type: Article

References (34)

1. Smith TF, Gaitatzes C, Saxena K, Neer EJ. The WD repeat: A common architecture for diverse functions. Trends Biochem. Sci. 1999 24 : 181 5.
2. Neer EJ, Schmidt CJ, Nambudripad R, Smith TF. The ancient regulatory-protein family of WD-repeat proteins. Nature 1994 371 : 297 300.
3. Neer EJ, Smith TF. G protein heterodimers: New structures propel new questions. Cell 1996 84 : 175 8.
4. Ishikawa N, Feng GG, Ito Y et al. A role of anti-verotoxin antibody immunoreactive peptide, Virp5, from rat spinal cord. Peptides 2004 25 : 1909 16.
5. An J, Tsunekawa K, Feng GG et al. Roles of naofen, a novel WD-repeat-2 protein, in the CCl4-treated livers: A possible relationship to cell proliferation. Eur. J. Pharmacol. 2008 587 : 285 90.
6. Physiological Society of Japan. Guiding principles for the care and use of animals in the field of physiological sciences. J. Physiol. Soc. Jpn. 2000 64 : 143 6.
7. Lee YJ, Shin SJ, Tan MS, Hsieh TJ, Tsai JH. Increased renal atrial natriuretic peptide synthesis in rats with deoxycorticosterone acetate-salt treatment. Am. J. Physiol. 1996 271 : F779 89.
8. Morita H, Takeuchi T, Suzuki S et al. Aortic endothelial cells synthesize a large chondroitin sulphate proteoglycan capable of binding to hyaluronate. Biochem. J. 1990 265 : 61 8.
9. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001 25 : 402 8.
10. Bates JN, Baker MT, Guerra Jr. R, Harrison DG. Nitric oxide generation from nitroprusside by vascular tissue. Evidence that reduction of the nitroprusside anion and cyanide loss are required. Biochem. Pharmacol. 1991 42 (Suppl S157 65.
11. Appel LJ, Brands MW, Daniels SR, Karanja N, Elmer PJ, Sacks FM. Dietary approaches to prevent and treat hypertension: A scientific statement from the American Heart Association. Hypertension 2006 47 : 296 308.
12. Dolan E, Stanton A, Thijs L et al. Superiority of ambulatory over clinic blood pressure measurement in predicting mortality: The Dublin outcome study. Hypertension 2005 46 : 156 61.
13. Chobanian AV, Bakris GL, Black HR et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report. JAMA 2003 289 : 2560 72.
14. Schini VB, Durante W, Elizondo E et al. The induction of nitric oxide synthase activity is inhibited by TGF-beta 1, PDGFAB and PDGFBB in vascular smooth muscle cells. Eur. J. Pharmacol. 1992 216 : 379 83.
15. Schini VB, Catovsky S, Durante W, Scott-Burden T, Schafer AI, Vanhoutte PM. Thrombin inhibits induction of nitric oxide synthase in vascular smooth muscle cells. Am. J. Physiol. 1993 264 : H611 16.
16. Junquero DC, Schini VB, Scott-Burden T, Vanhoutte PM. Transforming growth factor-beta 1 inhibits l-arginine-derived relaxing factor(s) from smooth muscle cells. Am. J. Physiol. 1992 262 : H1788 95.
17. Scott-Burden T, Schini VB, Elizondo E, Junquero DC, Vanhoutte PM. Platelet-derived growth factor suppresses and fibroblast growth factor enhances cytokine-induced production of nitric oxide by cultured smooth muscle cells. Effects on cell proliferation. Circ. Res. 1992 71 : 1088 100.
18. Durante W, Schini VB, Catovsky S, Kroll MH, Vanhoutte PM, Schafer AI. Plasmin potentiates induction of nitric oxide synthesis by interleukin-1 beta in vascular smooth muscle cells. Am. J. Physiol. 1993 264 : H617 24.
19. Ito H, Majima M, Nakajima S, Hayashi I, Katori M, Izumi T. Effect of prolonged administration of a urinary kinase inhibitor, ebelactone B on the development of deoxycorticosterone acetate-salt hypertension in rats. Br. J. Pharmacol. 1999 126 : 613 20.
20. Wang Q, Domenighetti AA, Pedrazzini T, Burnier M. Potassium supplementation reduces cardiac and renal hypertrophy independent of blood pressure in DOCA/salt mice. Hypertension 2005 46 : 547 54.
21. Pérez-Rivera AA, Fink GD, Galligan JJ. Vascular reactivity of mesenteric arteries and veins to endothelin-1 in a murine model of high blood pressure. Vasc. Pharmacol. 2005 43 : 1 10.
22. Michel JB, Sayah S, Guettier C et al. Physiological and immunopathological consequences of active immunization of spontaneously hypertensive and normotensive rats against murine renin. Circulation 1990 81 : 1899 910.
23. Kirchner KA, Scanlon Jr. PH, Dzielak DJ, Hester RL. Endothelium-derived relaxing factor responses in Doca-salt hypertensive rats. Am. J. Physiol. 1993 265 : R568 72.
24. Moncada S, Palmer RM, Higgs EA. Nitric oxide physiology, pathophysiology, and pharmacology. Pharmacol. Rev. 1991 43 : 109 42.
25. Murad F. Cyclic guanosine monophosphate as a mediator of vasodilation. J. Clin. Invest. 1986 78 : 1 5.
26. Ignarro JL. Biological actions and properties of endothelium-derived nitric oxide formed and released from artery and vein. Circ. Res. 1989 65 : 1 21.
27. Hatakeyama K, Inoue Y, Harada T, Kagamiyama H. Cloning and sequencing of cDNA encoding rat GTP cyclohydrolase I. The first enzyme of the tetrahydrobiopterin biosynthetic pathway. J. Biol. Chem. 1991 266 : 765 9.
28. Ota A, Ichinose H, Nagatsu T. Mouse sepiapterin reductase: An enzyme involved in the final step of tetrahydrobiopterin biosynthesis. Primary structure deduced from the cDNA sequence. Biochim. Biophys. Acta 1995 1260 : 320 2.
29. Thöny B, Auerbach G, Blau N. Tetrahydrobiopterin biosynthesis, regeneration and functions. Biochem. J. 2000 347 : 1 16.
30. Nichol CA, Smith GK, Duch DS. Biosynthesis and metabolism of tetrahydrobiopterin and molybdopterin. Annu. Rev. Biochem. 1985 54 : 729 64.
31. Milstien S, Kaufman S. The biosynthesis of tetrahydrobiopterin in rat brain. Purification and characterization of 6-pyruvoyl tetrahydropterin (2′-oxo) reductase. J. Biol. Chem. 1989 264 : 8066 73.
32. Shiraishi H, Kato T, Atsuta K et al. cGMP inhibits GTP cyclohydrolase I activity and biosynthesis of tetrahydrobiopterin in human umbilical vein endothelial cells. J. Pharmacol. Sci. 2003 93 : 265 71.
33. Dzielak DJ, Norman Jr. RA. Renal nerves are not necessary for onset or maintenance of DOCA-salt hypertension in rats. Am. J. Physiol. 1985 249 : H945 9.
34. Huang M, Hester RL, Guyton AC, Norman Jr. RA. Hemodynamic studies in DOCA-salt hypertensive rats after opening of an arteriovenous fistula. Am. J. Physiol. 1992 262 : H1802 8.